Thai mRNA vaccine developers call for it to be accelerated for emergency use


The developers of Thailand’s first mRNA-based Covid-19 vaccine are urging the Food and Drug Administration to approve it for emergency use while the booster rolls out. The Bangkok Post reports that, in an effort to become self-sufficient in vaccine manufacturing, the government has allocated a budget of 1 billion baht for developers.

The mRNA-based ChulaCov19 vaccine is under development at Chulalongkorn University, under the leadership of Kiat Ruxrungtham. He says the team is now concerned that by the time the development process is complete, at least 70% of the population will already be fully vaccinated. It is asking the FDA to allow approval of the ChulaCov19 vaccine for emergency use in human trials, alongside the booster vaccines currently in use.

“We will review the case with the FDA to come to a conclusion. If so, we might see a place to use it for the booster vaccine. “

The developer of another Thai vaccine, inactivated HXP-GPOVac, agrees, saying normal FDA regulations may further delay the time to market for local vaccines. Both HXP-GPOVac and ChulaCov19 are in phase 2 human trials, with Baiya Phytopharm’s tobacco vaccine entering phase 1.

For more information on Covid-19 insurance, CLICK HERE.

THE SOURCE: Bangkok Post

Get more from The Thaiger

Download our app on Android or iOS
Give your opinion on our Thailand forums
Subscribe to our daily email newsletter
Subscribe / Join YouTube for Daily Shows
Like / Follow us on Facebook
Follow us on Twitter
FOLLOW US on Instagram


Leave A Reply